Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 5/20 | 0.49 |
| ▸ | CLPP | Q16740 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4464468 | 0.87 | HCAR3 (0.49) | MLYCDSMN1; SMN2ITGB1ITGA5ALDH1A1 | |
| SCHEMBL14236793 | 0.82 | TSHR (0.57) | MLYCDSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL3585691 | 0.80 | LMNA (0.56) | SMN1; SMN2ITGB1ITGA5ALDH1A1HIF1A | |
| SCHEMBL5095907 | 0.80 | ALDH1A1 (0.44) | CLPPSMN1; SMN2ITGB1ITGA5ALDH1A1 | |
| SCHEMBL2934580 | 0.79 | ATM (0.42) | MLYCDCLPPALDH1A1KMT2AHCAR3 | |
| SCHEMBL28371978 | 0.79 | SMN1; SMN2 (0.51) | CLPPSMN1; SMN2ITGB1ITGA5ALDH1A1 | |
| SCHEMBL4302375 | 0.77 | PDK1 (0.52) | CLPPSMN1; SMN2ITGB1ITGA5ALDH1A1 | |
| SCHEMBL1298401 | 0.76 | HSP90AA1 (0.48) | MLYCDSMN1; SMN2ALDH1A1HCAR3MAPT | |
| SCHEMBL3727544 | 0.76 | THRB (0.52) | CLPPSMN1; SMN2ITGB1ITGA5ALDH1A1 | |
| SCHEMBL12061581 | 0.75 | ALDH1A1 (0.51) | CLPPSMN1; SMN2ITGB1ITGA5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236965-B2 | Benzimidazole derivatives and their use as a medicament | IPSEN PHARMA S.A.S. (FR) | 2012-08-07 | — | — | US | disclosed |
| US-20090170922-A1 | Benzimidazole derivatives and their use as a medicament | SOCIETE DE CONSEILS DE RECHERECHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2009-07-02 | — | — | US | disclosed |
| US-7495110-B2 | Benzimidazole derivatives and their use as GnRH antagonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-02-24 | — | — | US | disclosed |
| EP-1467974-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS GNRH ANTAGONISTS | SOD CONSEILS RECH APPLIC (FR) | 2007-08-15 | — | — | EP | disclosed |
| US-20050049290-A1 | Benzimidazole derivatives and their use as gnrh antagonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) (FR) | 2005-03-03 | — | — | US | disclosed |
| EP-1467974-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS GNRH ANTAGONISTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A. (FR) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003053939-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS GNRH ANTAGONISTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170922-A1 | Benzimidazole derivatives and their use as a medicament | GNRHR, FSHR, KISS1R | MLYCD 2239/4885CLPP 3791/4885SMN1; SMN2 4699/4885 |
| US-20050049290-A1 | Benzimidazole derivatives and their use as gnrh antagonists | GNRHR, FSHR, KISS1R | MLYCD 2444/4885CLPP 4254/4885SMN1; SMN2 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.